Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) has been assigned an average rating of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $18.38.

Several research firms have issued reports on TERN. Oppenheimer increased their price objective on Terns Pharmaceuticals from $17.00 to $20.00 and gave the stock an "outperform" rating in a research note on Wednesday, December 4th. HC Wainwright reiterated a "neutral" rating and set a $7.50 target price on shares of Terns Pharmaceuticals in a research report on Wednesday, December 4th. William Blair reaffirmed a "market perform" rating on shares of Terns Pharmaceuticals in a research note on Friday, March 21st. Finally, JMP Securities restated a "market outperform" rating and set a $20.00 price target on shares of Terns Pharmaceuticals in a research report on Wednesday, December 4th.

Terns Pharmaceuticals Price Performance

Shares of Terns Pharmaceuticals stock traded down $0.20 during midday trading on Tuesday, hitting $2.92. The company had a trading volume of 555,610 shares, compared to its average volume of 1,489,492. Terns Pharmaceuticals has a 1-year low of $2.91 and a 1-year high of $11.40. The business's 50 day simple moving average is $3.93 and its two-hundred day simple moving average is $5.95. The stock has a market cap of $254.91 million, a PE ratio of -2.47 and a beta of -0.30.

Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.06. On average, sell-side analysts expect that Terns Pharmaceuticals will post -1.19 EPS for the current fiscal year.

Insider Activity

In related news, CFO Mark J. Vignola sold 9,059 shares of Terns Pharmaceuticals stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $5.80, for a total transaction of $52,542.20. Following the completion of the transaction, the chief financial officer now owns 74,752 shares in the company, valued at approximately $433,561.60. This trade represents a 10.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Emil Kuriakose sold 4,481 shares of the company's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $5.71, for a total value of $25,586.51. Following the completion of the sale, the insider now owns 54,269 shares in the company, valued at $309,875.99. This represents a 7.63 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 36,669 shares of company stock valued at $211,040. 15.10% of the stock is owned by insiders.

Institutional Trading of Terns Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Landscape Capital Management L.L.C. bought a new position in Terns Pharmaceuticals during the fourth quarter worth about $73,000. Townsquare Capital LLC acquired a new stake in shares of Terns Pharmaceuticals in the fourth quarter valued at approximately $76,000. Sio Capital Management LLC bought a new stake in shares of Terns Pharmaceuticals in the third quarter valued at approximately $83,000. Oxford Asset Management LLP acquired a new stake in Terns Pharmaceuticals during the fourth quarter worth approximately $86,000. Finally, Savant Capital LLC bought a new position in Terns Pharmaceuticals during the 4th quarter worth $89,000. Institutional investors own 98.26% of the company's stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.